Scribe Therapeutics Inc. (SCTX)

NASDAQ Healthcare Biotechnology

Scribe Therapeutics Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Alameda, CA, US. The stock last traded at $17.96, down 6.94% on the session, giving a market capitalisation of $290.6M. Its beta of 0.00 implies it has historically moved less than the broad market.

Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.